RECRUITINGINTERVENTIONAL
Exploring the Recovery Function of Sleep in Neurodegeneration
Exploring the Recovery Function of Sleep in Neurodegeneration - an Observational Cross-Sectional Study
About This Trial
The overall objective of this study is to identify the best approach for assessing the recovery function of sleep in neurodegenerative diseases associated with abnormal protein aggregation with regard to the conception of future intervention studies. To this end, the investigators will follow an exploratory approach in a preferably broad data set collected in patients with neurodegenerative diseases associated with abnormal protein aggregation and in healthy humans.
Who May Be Eligible (Plain English)
Who May Qualify:
- Good general health or confirmed diagnosis of neurodegenerative disease associated with abnormal protein aggregation along international criteria
- Age above 18 years
- In ambulant setting: ability to apply the ambulant EEG device for the duration of the study, either alone or with help of co-habitant if MoCA \< 20
Who Should NOT Join This Trial:
- Failure to give willing to sign a consent form
- Inability to follow the procedures of the study, e.g. due to language problems or cognitive deficits
- Known or suspected non-compliance, drug- or medication abuse
- Inability to hear the tones to be applied during sleep in auditory stimulation experiments
- Skin disorders/problems/allergies in face/ear area that could worsen with electrode application
- Regular intake of drugs that may alter the relationship between sleep and outcome variables under investigation (opioids, benzodiazepines and z-drugs (nonbenzodiazepines)).
- Clinically significant concomitant disease states
- Too high (disease) burden for patients
- Additional non-medical exclusion criteria may be defined for certain cognitive tasks (e.g. no glasses during experiments involving eye tracking)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Good general health or confirmed diagnosis of neurodegenerative disease associated with abnormal protein aggregation along international criteria
* Age above 18 years
* In ambulant setting: ability to apply the ambulant EEG device for the duration of the study, either alone or with help of co-habitant if MoCA \< 20
Exclusion Criteria:
* Failure to give informed consent
* Inability to follow the procedures of the study, e.g. due to language problems or cognitive deficits
* Known or suspected non-compliance, drug- or medication abuse
* Inability to hear the tones to be applied during sleep in auditory stimulation experiments
* Skin disorders/problems/allergies in face/ear area that could worsen with electrode application
* Regular intake of drugs that may alter the relationship between sleep and outcome variables under investigation (opioids, benzodiazepines and z-drugs (nonbenzodiazepines)).
* Clinically significant concomitant disease states
* Too high (disease) burden for patients
* Additional non-medical exclusion criteria may be defined for certain cognitive tasks (e.g. no glasses during experiments involving eye tracking)
Treatments Being Tested
BEHAVIORAL
Auditory stimulation
Auditory stimulation during sleep
Locations (1)
University Hospital Zurich, Neurology department
Zurich, Canton of Zurich, Switzerland